Importantly, the discovery of novel strategies, such as PROTACs to target IRAK4, could not only support the understanding of IRAK4 biology but could also lead to the development of new therapeutic agents to treat inflammatory and neoplastic diseases. This evidence concerns the gene IRAK4 and neoplasm.